Testosterone can increase platelet counts, though the effect is modest compared to its well-known impact on red blood cells. Clinical trials show that men receiving testosterone saw platelet counts rise by roughly 8,000 to 9,000 cells per microliter, a small but measurable shift within the normal range. The more clinically significant concern is how testosterone changes platelet behavior, making them stickier and more prone to clotting.
What the Clinical Trials Show
Two trials have directly measured platelet changes in men receiving testosterone. In the 5-alpha Reductase Trial, men given weekly testosterone injections at various doses showed a dose-dependent increase in platelet counts. The lowest dose (50 mg/week) actually produced a slight decrease, while doses of 125 mg, 300 mg, and 600 mg per week all raised platelet counts by about 8,000 to 9,000 cells per microliter. The dose-response trend was statistically significant.
A second trial, called OPTIMEN, found a similar bump. Men receiving 100 mg of testosterone per week saw platelet counts rise by roughly 9,000 cells per microliter from baseline. To put that in perspective, a normal platelet count falls between 150,000 and 450,000 per microliter. An increase of 9,000 is unlikely to push someone from a normal count into the abnormal range on its own. Thrombocytosis, the clinical term for a dangerously high platelet count, isn’t diagnosed unless platelets exceed 450,000 per microliter.
How Testosterone Affects Platelet-Producing Cells
Platelets are produced by large bone marrow cells called megakaryocytes. Both megakaryocytes and mature platelets carry androgen receptors, the molecular docking stations that testosterone binds to. Research on human stem cells shows that as megakaryocytes mature, they express more of these receptors, making them increasingly responsive to testosterone.
Interestingly, the relationship isn’t linear. Moderate concentrations of testosterone (1 to 10 nanomoles per liter) increase receptor expression on megakaryocytes, while very high concentrations (100 nanomoles per liter) actually suppress it. This may partly explain why the platelet count increase in clinical trials plateaus at higher doses rather than continuing to climb. It also suggests that megakaryocytes have a regulated, not runaway, response to testosterone.
Platelet Stickiness Matters More Than Count
The number of platelets circulating in your blood is only part of the picture. Testosterone also changes how those platelets behave. Research published in Circulation found that testosterone increases the density of a specific receptor on platelet surfaces that promotes clumping. Platelets with more of these receptors produce more of a chemical signal called thromboxane A2, which triggers aggregation, the process by which platelets clump together to form clots.
This means testosterone can make your existing platelets more reactive, not just more numerous. For most healthy men, this shift is clinically insignificant. But for men with other cardiovascular risk factors, such as obesity, smoking, or a history of blood clots, the combination of stickier platelets and thicker blood can tip the balance toward a clotting event.
The Bigger Blood Change: Red Blood Cells
While platelet changes from testosterone are modest, the effect on red blood cells is much more pronounced and is the primary blood-related concern during testosterone therapy. Testosterone stimulates red blood cell production by increasing iron availability. It does this by suppressing hepcidin, a hormone that normally locks iron away in storage. With more iron available, the bone marrow produces red blood cells at a higher rate, raising both hemoglobin and hematocrit (the percentage of blood volume occupied by red cells).
This condition, called erythrocytosis, is the most common side effect of testosterone therapy. When hematocrit rises too high, blood becomes thicker and more viscous, which independently increases the risk of both arterial and venous blood clots. Thrombosis is a recognized consequence of erythrocytosis even in people whose platelet counts remain normal. So while testosterone’s effect on platelets adds a layer of risk, the thickening of blood from excess red blood cells is the larger driver of clotting complications.
What Gets Monitored and Why
Standard monitoring guidelines for men on testosterone therapy call for a hematocrit check at baseline, again at 3 to 6 months after starting treatment, and annually thereafter. If hematocrit exceeds 54%, the recommendation is to pause therapy until levels drop, evaluate for contributing factors like sleep apnea, and restart at a lower dose.
Platelet counts are captured automatically as part of a complete blood count, the same test that measures hematocrit. So your platelets will be tracked even though they aren’t the primary target of monitoring. If you’re on testosterone therapy and notice your platelet count creeping upward on lab results, the increase is likely real but small. The number to watch more closely is hematocrit, which tends to rise faster and higher, and which carries the greater share of clotting risk.
Who Should Pay Closer Attention
For men starting testosterone therapy with platelet counts already near the upper end of normal, even a small increase could warrant closer monitoring. The same applies to men with a personal or family history of blood clots, those with clotting disorders, or anyone taking medications that also affect platelet function. Herbal supplements marketed as testosterone boosters can also contribute to these blood changes, since the underlying mechanism is hormone-driven polycythemia rather than something unique to prescription testosterone.
The bottom line: testosterone does increase platelet counts, but by a small amount that rarely crosses into a dangerous range on its own. Its effect on platelet stickiness and red blood cell production is more clinically meaningful, and those changes together are what create the elevated clotting risk associated with testosterone therapy.